To obtain an unbiased estimation, the performance of the biomarker will be validated in another ongoing cohort of replication.
Detected variations which were found in the affected cat were validated in a replication cohort of 42 healthy cats.
Six miRNAs that showed significantly different expression in the two tumor classes were validated in a replication set of three nodular and four infiltrative samples.
Quantitative polymerase chain reaction assays were developed for six of the miRNAs that showed significant differences between the BCC subtypes, and five of these six were validated in a replication set of four infiltrative and three nodular tumors.
Finally, 5 of the 8 SNPs that were validated in the Spanish replication cohort were not associated with the disease in the US population.
RARs in the discovery set that were found to be significantly associated with prognosis were validated in an independent replication set.
The results were validated in 12 independent replication cohorts of European ancestry (combined N = 22 789) that were a part of the International Glaucoma Genetics Consortium.
We hypothesized that the results of our miR-eQTL mapping might help to clarify many of the associations found in the NHGRI catalog of published genome-wide association analyses, most of which have been validated in a subsequent replication study.
Although the two new susceptibility genes were identified through GWA studies in large number of cases, disease susceptibility has to be validated via replication study in more populations.
The initial finding was validated in four out of five replication samples, involving a total of 9,881 individuals, with a combined odds ratio (OR) of 1.22 (1.05–1.42) under a recessive model [1].
